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The last two decades have witnessed consider-
able changes in the treatment of patients with
peripheral arterial occlusive disease. Indications for
percutaneous intervention continue to expand to
include an increasing number of conditions that pre-
viously would have been managed either conserva-
tively or surgically. This trend is accompanied by
ongoing discussion about the optimal treatment
strategy for particular patient groups.1-7 Restricted
health care budgets have led to an increasing aware-
ness of the financial costs of revascularization proce-
dures, and costs currently play an important role in
decision making.8-12
Whereas many cost-identification analyses of
revascularization procedures for peripheral arterial
occlusive disease have focused on the intervention
itself,5,7 the total in-hospital costs of intervention are
determined by more factors. Additional costs may be
incurred for the management of procedure-related
complications, adjuvant therapy for ischemic ulcers
or gangrene, and management of comorbidity relat-
ed to age, sex, and cardiovascular risk factors.
Furthermore, hospital overhead costs are underesti-
mated or omitted when focus is on the procedure
itself. A cost analysis from the hospital perspective
should take into consideration all costs incurred by
the hospital, whether they were incurred by the
department performing the procedure or by anoth-
er department.13,14 An analysis from the societal
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perspective would also consider physician fees, nurs-
ing home costs, home health services, costs incurred
in the future, production losses, and costs borne by
the patient and his or her family.13,14
Previously reported estimates of hospital costs
for femoropopliteal revascularization procedures
indicated an increase in the average costs for
femoropopliteal percutaneous transluminal angio-
plasty (PTA) over the years 1986 through 1991,
whereas the average costs for femoropopliteal bypass
surgery showed a decrease.1 These results suggest
that costs may change considerably over time as new
techniques and practice patterns evolve. The impli-
cation is that optimal decision making requires reg-
ularly updated cost estimates. The purposes of this
study were to determine the total average in-hospi-
tal costs of various revascularization procedures for
peripheral arterial occlusive disease; to determine the
additional costs of local and systemic complications
and the effect of patient characteristics such as age,
sex, pretreatment symptoms, and cardiovascular risk
factors; and to examine whether costs for peripheral
revascularization have changed since 1990.
METHODS
Patient population and data collection. We
examined medical records of all patients admitted
from 1990 through 1995 to the Brigham and
Women’s Hospital for a percutaneous or surgical
revascularization procedure for peripheral arterial
occlusive disease (n = 737). We excluded from analy-
sis patients with additional interventions during the
same admission (n = 154), leaving 583 patients for
the analysis. The additional interventions included
procedures that were not related to the revasculariza-
tion, such as interventions for gastrointestinal, onco-
logic, and pulmonary disorders (n = 62). We also
excluded patients with additional cardiovascular pro-
cedures during the same admission that were not
peripheral revascularization procedures, such as heart
valve replacement and septal operations, coronary
artery bypass grafting, percutaneous transluminal
coronary angioplasty, insertion of cardiac pacemaker
systems, intubation, heart transplantation, and aortic
resection and replacement (n = 78). Also excluded
were patients with a peripheral arterial occlusive dis-
ease procedure that was not one of the procedures of
interest (n = 14). If the procedure was necessitated
by complications within 30 days of the primary pro-
cedure, it was not excluded from analysis.
The data included in our study partly overlapped
with those of a previous report.1 The previous study
reported the hospital costs of femoropopliteal pro-
cedures performed from 1986 through 1991. In this
study, we analyzed a more recent time period and a
wider range of interventions, including suprain-
guinal procedures and endarterectomy.
Patient and intervention characteristics were col-
lected prospectively as part of routine clinical prac-
tice and recorded in a computerized registry data-
base. The information recorded included age, sex,
pretreatment symptoms (intermittent claudication
versus critical ischemia), diabetes (insulin-dependent
diabetes mellitus or non–insulin-dependent diabetes
mellitus requiring oral medication), use of antihy-
pertensive medication as a marker of hypertension,
coronary artery disease (history of angina, myocar-
dial infarction, percutaneous transluminal coronary
angioplasty, or coronary artery bypass surgery), con-
gestive heart failure (requiring digoxin or diuretics),
and renal failure (creatinine level >1.6 mg/dL). 
Twelve types of revascularization procedures
were identified. They included aortic bifurcation
bypass (aortoiliac, aortofemoral), femoropopliteal
bypass (above or below knee), femoroinfrapop-
liteal bypass, femorofemoral bypass, axillobifemoral
bypass, iliofemoral bypass, popliteoinfrapopliteal
bypass, iliac artery PTA with or without stent,
femoropopliteal PTA, and endarterectomy. Systemic
and local complications were also recorded. A sys-
temic complication was defined as damage or disease
with a serious health impact related to the procedure
and involved any organ or tissue other than the
peripheral arterial system or surgical wound. Only
new disorders were considered complications. If, for
example, the patient had a history of congestive heart
failure and experienced another episode within 30
days of the intervention, it was classified as an exac-
erbation of a preexisting illness and not as a systemic
complication. A fatal systemic complication was
defined as a systemic complication that led to death
within 30 days of the procedure or during hospital-
ization. A local complication was defined as nonfatal
procedure-related damage or disease that involved
the peripheral arterial system or the wound related to
the intervention or operation but excluded short-
and long-term failures such as graft thrombosis or
failed PTA.
Hospital costs. Cost data were obtained from
the hospital inpatient accounting database. Total
hospital costs included the costs of the intervention,
routine and intensive care room and board, operat-
ing room services, diagnostic angiography, clinical
laboratory services (eg, hematology, microbiology,
and chemistry), patient laboratory services (eg, elec-
trocardiography and noninvasive testing), pharmacy
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(all medications), blood bank, and other inpatient
services related to the intervention (eg, physical
therapy, hemodialysis, and respiratory therapy).
Physician fees were excluded from this analysis.
To determine the economic effect of health care
services on the budget, estimates of actual econom-
ic costs are required to represent the value of the
resources used. Hospital administrative and account-
ing systems usually record charges rather than the
actual costs per admission. The number may be mis-
leading, because charges and costs need not be the
same. Charges, as billed to third-party payers, often
exceed the actual costs, but it is also possible that the
actual costs exceed the charges. The costs for any
particular cost center can be obtained with tradi-
tional tools of cost accounting. General costs such as
housing, housekeeping, administration, and hospital
overhead are allocated across revenue-collecting cost
centers with a measure such as square footage. The
charges billed by the different cost centers also are
known. This enables calculation of a cost-to-charge
ratio per cost center per fiscal year. For example, the
cost-to-charge ratio for the various cost centers
within diagnostic radiology ranged from 0.57 to
1.11, for microbiology, chemistry, and hematology
the ratio ranged from 0.19 to 0.38, and for room
and board from 0.90 to 1.13. These cost-to-charge
ratios can be used to estimate the underlying costs of
a procedure by means of multiplying the charges for
that procedure with the appropriate cost-to-charge
ratios.1,14 In this analysis, total costs per admission
were calculated as the aggregate of the charges per
cost center multiplied by the center-specific and
year-specific cost-to-charge ratios. All costs were
adjusted to 1995 US dollars by means of the med-
ical care–specific consumer price index (Bureau of
Labor Statistics). Length of stay was defined as the
number of days from date of admission to date of
discharge.
Data analysis. The average total hospital costs
for the 12 different procedures were calculated. To
examine the effect of patient characteristics and pro-
cedure-related complications on the total costs per
admission, a multiple linear regression analysis was
performed with the costs as the dependent variable.
Using dummy variables, we included as covariates
the type of procedure and variables for local compli-
cations, fatal systemic complications, and nonfatal
systemic complications. A selection of patient char-
acteristics was included on the basis of statistical sig-
nificance in a multiple regression analysis (P < .05).
Separate models for the different procedures were
not constructed, which implies that we assumed the
extra costs incurred from a particular complication
would be the same, regardless of the procedure that
caused the complication. We also assumed that the
effect on costs of the patient characteristics was inde-
pendent of the type of intervention. The validity of
these assumptions was explored by means of adding
interaction terms which combined the type of inter-
vention (herein defined as bypass surgery versus
PTA) with the other variables in the model.
In similar regression analyses, we examined the
relation between costs and the year of the interven-
tion. Separate models were constructed for four
groups of interventions, as follows: iliac PTA,
femoropopliteal PTA, femoropopliteal or femoroin-
frapopliteal bypass surgery, and aortic bifurcation
bypass surgery. We included as explanatory variables all
variables selected in the former step, plus the year of
intervention as a continuous variable, assuming a lin-
ear effect. For all statistical analyses, SPSS for Windows
release 6.1.2 (SPSS Inc, Cary, NC) was used.
RESULTS
Table I presents the patient characteristics of the
study population. The average age was 65.6 years,
and 47% of the population were women. Most of the
patients sought treatment for critical ischemia
(61%). Table II presents the total costs per admis-
sion for the 12 different procedures. We restricted
our data collection to admissions for revasculariza-
tion procedures; thus percutaneous procedures on
an outpatient basis were excluded. Average costs var-
ied from $9365 for femoropopliteal PTA to
$23,732 for aortic bifurcation bypass surgery. For all
types of interventions, the costs per admission varied
considerably. The standard deviation ranged from
33% to 60% of the mean.
In the multiple linear regression analysis, statisti-
cally significant effects of fatal and nonfatal systemic
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Table I. Patient characteristics (n = 583)
Characteristic Value
Age (y; mean and range) 65.6 (24-93)
Sex (% female) 47
Pretreatment symptoms (% claudication/ 39/61
% critical ischemia)
Congestive heart failure (%) 6
Coronary artery disease (%) 47
Chronic obstructive pulmonary disease (%) 11
Diabetes (%) 37
Hypertension (%) 53
Renal failure (%) 8
Smoking (%) 44
Stroke (%) 10
complications, age, sex, pretreatment symptoms,
and coronary artery disease were demonstrated
(Table III). After correction for type of procedure,
17% of the variation was explained by these factors.
Four and one-half percent of the interventions were
associated with a nonfatal systemic complication and
0.7% with a fatal systemic complication. The esti-
mated additional costs incurred for nonfatal and
fatal systemic complications were $9345 and
$11,675, respectively. Five and eight-tenths percent
of the interventions were associated with a local
complication. These complications did not influence
the total costs significantly. Patients younger than 50
years of age incurred $2569 less, whereas those
older than 80 years incurred $1345 more than the
reference group of 51-year-old to 70-year-old
patients. Pretreatment critical ischemia, female sex,
and coronary heart disease all significantly increased
the costs with estimates of $4478, $1461, and
$1287, respectively.
To examine the validity of our assumptions that
the effects of complications and patient characteris-
tics were independent of the type of intervention, we
entered interaction terms combining the type of
intervention (herein defined as surgical versus per-
cutaneous intervention) and the other variables in
the model. None of the interaction terms was statis-
tically significant, implying there was no evidence to
suggest that the incremental costs depended on the
type of intervention. Because there was no interac-
tion between the type of intervention (bypass versus
PTA) and complications, we assumed that the extra
costs incurred by a particular complication were
independent of which procedure was performed.
The regression coefficients were used to estimate
total average in-hospital costs for specific patient
groups, as predicted with the regression model. The
last column in Table II presents the results adjusted
to represent 51-year-old to 70-year-old men without
coronary artery disease treated for intermittent clau-
dication; it was assumed that the procedure was
uncomplicated. For other situations, the costs can be
estimated by means of combining the information
from the last column of Table II with the incremen-
tal costs in the second column of Table III. For
example, the predicted cost of an admission for
bifurcation bypass surgery for 71-year-old to 80-
year-old women treated for critical ischemia without
procedure-related complications would be 20,425 +
81 + 1461 + 4478 = 26,445 dollars. If one were to
include the potential financial consequences of a
complication, one would have to add the additional
costs for each type of complication, each weighed
with the corresponding probability of occurrence.
In a separate regression analysis, the cost of one
extra day in the hospital was estimated. As with the
foregoing analysis, we adjusted for type of proce-
dure, complications, and patient characteristics. The
results of this analysis indicated that the incremental
cost of one hospital day was $1025 (SD $39; P <
.001).
A separate regression analysis with the length of
stay as the dependent variable was performed to
determine the influence of complications on length
of stay. The results of this analysis suggested that
patients with a nonfatal systemic complication spent
an average of 4.2 extra days in the hospital (P <
.001). Patients with fatal systemic complications
spent 1.1 extra days in the hospital (P = 0.7). Adding
length of stay as an extra explanatory variable in the
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Table II. Total in-hospital costs and cost estimates adjusted to a reference patient group (1995 US dollars)
Mean value adjusted 
Procedure n Mean value ± SD for all to reference group*
Bifurcation bypass 68 23,732 ± 9074 20,425
Axillobifemoral bypass 11 23,127 ± 7599 15,152
Iliofemoral bypass 13 14,513 ± 8460 9,829
Femorofemoral bypass 40 15,470 ± 9326 11,532
Femoropopliteal bypass (above knee) 49 15,241 ± 7585 12,510
Femoropopliteal bypass (below knee) 88 16,986 ± 7587 12,495
Femoroinfrapopliteal bypass 186 20,216 ± 9821 14,114
Popliteoinfrapopliteal bypass 23 20,567 ± 9694 15,269
Endarterectomy 9 11,837 ± 5532 9,073
Iliac PTA common/external with stent 8 15,098 ± 5503 11,795
Iliac PTA common/external 50 10,351 ± 3704 8,261
Femoropopliteal PTA 38 9,365 ± 4366 6,489
*Adjusted by means of multiple linear regression model to represent 51-year-old to 70-year-old male patients with intermittent claudi-
cation who had no procedure-related complications.
original regression model suggested that 46% of the
additional costs incurred by a patient with a nonfatal
systemic complication can be explained by the
greater length of stay. For fatal complications, only
10% was explained by extra days in the hospital. For
some of the other significant explanatory variables in
the model, part of the effect on costs can be
explained by length of stay. Patients older than 80
years spent, on average, 2.5 extra days in the hospi-
tal (P = .004), whereas those 50 years or younger
spent, on average, 1.5 days less in hospital (P = .06)
compared with the reference group of 51- to 70-
year-old patients. Patients with critical ischemia
spent 2.7 more days in the hospital than patients
with intermittent claudication (P < .001). The addi-
tional costs of the explanatory variables sex and
coronary artery disease could not be explained by an
increase in length of stay.
Table IV presents the total average costs as a
function of time for four different groups of proce-
dures: iliac PTA, femoropopliteal or femoroin-
frapopliteal bypass operations, femoropopliteal PTA,
and aortic bifurcation bypass operations. As an illus-
tration, the costs of femoropopliteal PTA and
femoropopliteal bypass for 1986 to 1990, as report-
ed previously, are presented adjusted to 1995 US
dollars.1 The average costs for the year 1990 are the
weighted average costs from the previous and current
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Table III. Influence of age, critical ischemia, sex, procedure-related complications, and coronary artery
disease on total hospital costs (1995 US dollars)
Variable Effect on costs 95% Confidence interval P value
Age 50 y or younger* –2569 –4683; –455 .02
Age 71-80 y* 81 –1462; 1625 .02†
Age older than 80 y* 1345 –1016; 3707 .02
Female sex 1461 151; 2772 .03
Coronary artery disease 1287 –13; 2586 .05
Critical ischemia 4478 2983; 5972 <.001
Local complications –55 –2802; 2692 .97
Nonfatal systemic complications 9345 6181; 12,509 <.001
Fatal systemic complications 11,675 3796; 19,555 .004
*Age 51 to 70 years was used as the reference group.
†Multiple partial F test.
Table IV. Trends in cost and length of stay (1986–1995)
Mean cost ± SD Mean length
Procedure Years No. of patients (1995 US dollars) of stay ± SD (days)
Bifurcation graft 1990–1991 17 24,102 ± 6495 8.8 ± 2.8
1992–1993 27 24,516 ± 10,554 10.2 ± 4.6
1994–1995 24 22,589 ± 9078 7.8 ± 2.9
Femoropopliteal 1986–1987* 85 18,539* _
grafts 1988–1989 59 18,219* _
1990–1991 72 18,036 ± 8165 8.7 ± 4.2
1992–1993 123 19,590 ± 10,896 10.2 ± 9.3
1994–1995 128 17,918 ± 7665 8.1 ± 3.9
Iliac PTA 1990–1991 12 10,131 ± 2080 3.1 ± 2.7
1992–1993 23 10,228 ± 4246 2.9 ± 2.9
1994–1995 15 10,716 ± 4009 2.1 ± 1.9
Femoropopliteal 1986–1987* 12 9013* _
PTA 1988–1989* 13 9648* _
1990–1991 12 10,886 ± 5047 4.4 ± 5.7
1992–1993 23 8867 ± 4136 3.4 ± 6.5
1994–1995 3 7102 ± 365 1.3 ± 0.6
PTA, percutaneous transluminal angioplasty. 
*Averages are weighted averages of the 2 years and adjusted to 1995 US dollars.
From Hunink MGM, Cullen KA, Donaldson MC. Hospital costs of revascularization procedures for femoropopliteal arterial disease. 
J Vasc Surg 1994;19:632-41.
study. The costs for femoropopliteal PTA decreased
from $10,886 to $7102, but this trend was not sta-
tistically significant. Table IV demonstrates that the
decrease in costs was paralleled by a decrease in
length of stay. For the other procedures the cost esti-
mates were fairly stable over time. For all procedures,
the average length of stay during the years 1994
through 1995 was shorter than the average length of
stay during the years 1990 through 1993. After
adjustment for complications and other significant
variables, none of these trends over time was statisti-
cally significant (P values varied from .25 to .39).
DISCUSSION
Valid cost estimates may help identify the opti-
mal treatment strategy for patients with peripheral
arterial occlusive disease. Because costs may change
considerably over time, it is important that cost esti-
mates be updated regularly. In this study, we deter-
mined total average in-hospital costs for 12 different
revascularization procedures for peripheral arterial
occlusive disease. The cost estimates for the proce-
dures varied over a wide range. Fatal and nonfatal
systemic complications increased the total costs per
admission substantially. We also found statistically
significant effects of age, sex, pretreatment symp-
toms, and coronary artery disease. A comparison of
the costs of various procedures by year suggested a
decline in the costs for femoropopliteal PTA, but
this trend was not statistically significant.
A limitation of our study was that we restricted
our data collection to in-hospital revascularization
procedures. PTA and stent procedures are frequent-
ly performed in an outpatient setting, and thus our
cost estimates are probably overestimates of the
actual cost of such procedures. Not only is the in-
hospital setting more expensive, but also patients
who need admission for a percutaneous procedure
represent a selected group with more severe disease
and comorbidity and thus higher costs. With the
regression analysis, we were able to adjust for case
mix, but a true estimate of the costs of percutaneous
procedures performed on an outpatient basis neces-
sitates another study.
Another limitation of our study relates to the
method we used to estimate costs. The method is
based on charges adjusted with cost-to-charge ratios, a
method that has been shown to provide estimates
close to those obtained through cost accounting.14
Even though the cost-to-charge ratios were calculated
specifically for each cost center and each fiscal year, this
method is far from perfect. The method has the advan-
tage that all overhead costs are accounted for but the
disadvantage that all procedures within one cost center
are assumed to have the same cost-to-charge ratio.
This limitation in method may have affected the per-
cutaneous procedures to a greater extent than the sur-
gical procedures because of the introduction of expen-
sive new procedures in interventional radiology. Cost-
accounting methods currently being introduced in
hospitals nationwide should improve cost estimates
substantially. More sophisticated cost-accounting
methods were introduced at the Brigham and
Women’s hospital that allowed reestimation of the
cost-to-charge ratios. This analysis suggested that the
previously estimated cost-to-charge ratios in general
closely resemble those obtained with more sophisticat-
ed and elaborate cost-accounting methods.
A third limitation may be the restriction of data
collection from only one hospital, which is not repre-
sentative of the majority of hospitals in the United
States. Comparison of the average Medicare reim-
bursements for the fiscal year 1995 suggested that
reimbursements in Massachusetts are approximately
8% lower than the US average (Health Care Financing
Administration). On the other hand, the Brigham and
Women’s hospital is a teaching hospital with higher
costs than the average hospital in Massachusetts.
Third, cost estimates of different types of procedures
may be difficult to compare because of the differences
in case mix. To account for these differences we did,
however, adjust for several important factors, such as
complications and patient characteristics, in the regres-
sion analysis.
This study provided cost estimates for different
revascularization procedures and is intended mainly
for researchers performing cost-effectiveness analy-
ses. Although it is tempting to make direct compar-
isons between the costs of the procedures as pre-
sented, there are a number of caveats in doing so.
First, patients treated with percutaneous procedures
in this cohort were highly selected and admitted to
the hospital for treatment, which is not always nec-
essary. To make a fair comparison one would need to
adjust the costs for percutaneous procedures to
allow for treatment on an outpatient basis if possi-
ble. Second, comparison is useful only if different
intervention strategies are compared that take into
consideration the risk, effectiveness, and long-term
consequences of the treatment options. This was
beyond the scope of the current analysis.
The results of our analyses suggest that consider-
able extra costs are incurred because of systemic com-
plications. A likely explanation for these high addi-
tional costs is that patients with complications need
longer hospitalization. Support for this explanation
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was provided by a separate regression analysis with
length of stay as the dependent variable, which indi-
cated that patients with a nonfatal systemic complica-
tion spent an average of 4.2 extra days in the hospital
(P < .001). Another explanation for the extra costs for
patients with systemic complications may be that they
require more intensive care than other patients. As
expected, we also found that increasing age, coronary
artery disease, and critical ischemia increase costs sig-
nificantly. The fact that female sex was an important
predictor of increased costs could not be explained on
the basis of age, critical ischemia, or one of the other
variables in our regression analysis, nor could the dif-
ference be explained by the number of risk factors
among men (2.28) versus women (2.18). Thus we do
not have an explanation for this finding that can be
supported by our data.
A previous study demonstrated an increasing
trend in costs for femoropopliteal angioplasty and a
slight decreasing trend in costs for femoropopliteal
bypass surgery over the years 1986 through 1991.1
In this study we found a decline in costs for
femoropopliteal angioplasty over the years 1990
through 1995 (albeit not significant), paralleled by a
decrease in length of stay, and fairly stable costs for
the other procedures.
In conclusion, total in-hospital costs per admis-
sion for peripheral revascularization procedures are
highly variable and significantly increased by proce-
dure-related complications, increasing age, female
sex, therapy for critical ischemia, and the presence of
coronary artery disease. Statistically significant
trends over time were not demonstrated.
We thank Ms Julie Lombara for her assistance in
obtaining the Vascular Registry data.
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